Multicentric descriptive study of the lung cancer treatment

20109 Background: Given the insufficient available information on the clinical characteristics and the results of the lung cancer treatment at a population level, we performed a large multicentric descriptive study in the main hospitals in our city. Methods: We analyzed the patients diagnosed and treated for lung cancer during 1999 in five University Hospitals in Barcelona (Spain). We performed a retrospective analysis of the individual data obtained from the clinical records using a specifically validated questionnaire. A descriptive analysis was performed, stratifying for type of tumor, stage, and institution. The follow-up for the complete population was 5 years. Results: We included 836 patients (94.6% male, 5.4% female) with an average age of 64 years. Karnofsky was ≥ 70% in 85% of patients. Histologic distribution was non-small cell (NSCLC) 85.5%, small-cell (SCLC) 14.5%. 42% of cases were stage IV (38% NSCLC, 67.8% SCLC). First treatment was performed in 82% of cases with therapeutic intention (52% was chemotherapy). Pulmonary resection with lobectomy and platinum-based chemotherapy were the more frequent treatments. Complete remission was obtained in 25% of cases. Survival was 42.0, 17.9 and 12.6% at 1, 3 and 5 years respectively (NSCLC: 43.8, 19.4, 13.1%; SCLC: 31.9, 9.5, 9.5%). The mean interval first visit - treatment start was 2 months. The mean of direct costs per patient was 9000 €. The cost per life-year gained was 5200 € for NSCLC and 7600 € for SCLC patients. Conclusions: The obtained results allow to describe the clinical characteristics of a wide cohort of patients diagnosed of lung cancer and their survival to 5 years. Globally, these results are similar to those who have been published in our country and others, and constitute a very thorough referent for assessing the impact of future therapeutic advances. The comparison among hospitals can also be the matter of further analysis for identifying the causes of the observed differences. Equally, specific strategies for some patients’ subgroups could be designed in order to improve the cost-effectiveness of their treatment. No significant financial relationships to disclose.

Download Full-text

Patterns of Care for Non-Small Cell Lung Cancer Treatment -The Impact of Increased Consultant Site Specialisation; Quality vs Availability

International Journal of Cancer Research ◽

10.3923/ijcr.2006.84.90 ◽

2005 ◽

Vol 2 (1) ◽

pp. 84-90

Author(s):

A.J. Stewart ◽

C.R. Lewanski . ◽

H. Lee . ◽

P.M. Devlin .

Keyword(s):

Lung Cancer ◽

Cancer Treatment ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Patterns Of Care ◽

Small Cell Lung ◽

Lung Cancer Treatment ◽

The Impact

Download Full-text

The Impact of Residential Racial Segregation on Non-Small Cell Lung Cancer Treatment and Outcomes

The Annals of Thoracic Surgery ◽

10.1016/j.athoracsur.2021.04.096 ◽

2021 ◽

Author(s):

Chandler A. Annesi ◽

Michael Poulson ◽

Kimberley S. Mak ◽

Umit Tapan ◽

Tracey A. Dechert ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Treatment ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Racial Segregation ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Treatment ◽

The Impact

Download Full-text

2D Nanomaterial, Ti3C2 MXene-Based Sensor to Guide Lung Cancer Therapy and Management

Biosensors ◽

10.3390/bios11020040 ◽

2021 ◽

Vol 11 (2) ◽

pp. 40

Author(s):

Mahek Sadiq ◽

Lizhi Pang ◽

Michael Johnson ◽

Venkatachalem Sathish ◽

Qifeng Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Treatment ◽

Cancer Cells ◽

Small Cell ◽

Gas Chromatography Mass Spectrometry ◽

High Signal ◽

Research Attention ◽

Lung Cancer Treatment ◽

Anti Cancer ◽

Cox 2

Major advances in cancer control can be greatly aided by early diagnosis and effective treatment in its pre-invasive state. Lung cancer (small cell and non-small cell) is a leading cause of cancer-related deaths among both men and women around the world. A lot of research attention has been directed toward diagnosing and treating lung cancer. A common method of lung cancer treatment is based on COX-2 (cyclooxygenase-2) inhibitors. This is because COX-2 is commonly overexpressed in lung cancer and also the abundance of its enzymatic product prostaglandin E2 (PGE2). Instead of using traditional COX-2 inhibitors to treat lung cancer, here, we introduce a new anti-cancer strategy recently developed for lung cancer treatment. It adopts more abundant omega-6 (ω-6) fatty acids such as dihomo-γ-linolenic acid (DGLA) in the daily diet and the commonly high levels of COX-2 expressed in lung cancer to promote the formation of 8-hydroxyoctanoic acid (8-HOA) through a new delta-5-desaturase (D5Di) inhibitor. The D5Di does not only limit the metabolic product, PGE2, but also promote the COX-2 catalyzed DGLA peroxidation to form 8-HOA, a novel anti-cancer free radical byproduct. Therefore, the measurement of the PGE2 and 8-HOA levels in cancer cells can be an effective method to treat lung cancer by providing in-time guidance. In this paper, we mainly report on a novel sensor, which is based on a newly developed functionalized nanomaterial, 2-dimensional nanosheets, or Ti3C2 MXene. The preliminary results have proven to sensitively, selectively, precisely, and effectively detect PGE2 and 8-HOA in A549 lung cancer cells. The capability of the sensor to detect trace level 8-HOA in A549 has been verified in comparison with the traditional gas chromatography–mass spectrometry (GC–MS) method. The sensing principle could be due to the unique structure and material property of Ti3C2 MXene: a multilayered structure and extremely large surface area, metallic conductivity, and ease and versatility in surface modification. All these make the Ti3C2 MXene-based sensor selectively adsorb 8-HOA molecules through effective charge transfer and lead to a measurable change in the conductivity of the material with a high signal-to-noise ratio and excellent sensitivity.

Download Full-text